China Hepatitis B Producers Halt Production, Xinhua Weibo Says

China Hepatitis B Producers Halt Production, Xinhua Weibo Says

Three Chinese drug producers that make about 80 percent of the nation’s hepatitis B vaccines halted output because they don’t meet new production quality requirements, Xinhua News Agency said on its microblog.Beijing Tiantan Biological Products Corp. (600161), Shenzhen Kangtai Biological Products Co. and Dalian Hissen Bio-Pharm stopped production on Jan. 1, the official Xinhua agency’s Weibo microblog reported, citing the China Food and Drug Administration. The nation will ensure hepatitis B vaccine products meet market demand, according to Xinhua Weibo.

At least a dozen newborn babies have died nationwide after receiving hepatitis B shots, fueling concern about the safety of vaccines in China, Xinhua reported Dec. 31. China is investigating links between the deaths and hepatitis B vaccines that they were given as part of a national campaign to immunize against the liver disease, the People’s Daily reported Dec. 23.

The deaths are the latest test of China’s ability to ensure safe food and medicine after cases of tainted baby formula, fox meat sold as mutton and thousands of dead pigs found floating in Shanghai’s main river sparked public outrage. Authorities in March elevated the China Food and Drug Administration to a ministry-level agency to strengthen supervision.

China’s food and drug regulator on Dec. 20 suspended the use of all batches of a hepatitis B vaccine made by Shenzhen Kangtai Biological pending the results of a probe into its connection with the death of four infants. It had earlier on Dec. 13 halted use of two batches of the vaccine.

Vaccine Production

Kangtai Biological is “actively” assisting in the investigation and conducting its own tests, according to a Dec. 16 statement on its website. The company said it’s not yet clear if there are links between its vaccine and the deaths.

Two calls each to Kangtai Biological and Dalian Hissen’s general lines went unanswered after hours. A woman who answered Tiantan Biological’s general line and declined to identify herself, said no one was immediately available to comment.

The three companies accounted for about 80 percent of China’s hepatitis B vaccine output in January through November last year, Xinhua Weibo reported.

The vaccinations were added to China’s national immunization program in 2002 and have been free for all children since 2005, according to the Atlanta-based Centers for Disease Control and Prevention.

To contact Bloomberg News staff for this story: Sarah Chen in Beijing at

About bambooinnovator
Kee Koon Boon (“KB”) is the co-founder and director of HERO Investment Management which provides specialized fund management and investment advisory services to the ARCHEA Asia HERO Innovators Fund (, the only Asian SMID-cap tech-focused fund in the industry. KB is an internationally featured investor rooted in the principles of value investing for over a decade as a fund manager and analyst in the Asian capital markets who started his career at a boutique hedge fund in Singapore where he was with the firm since 2002 and was also part of the core investment committee in significantly outperforming the index in the 10-year-plus-old flagship Asian fund. He was also the portfolio manager for Asia-Pacific equities at Korea’s largest mutual fund company. Prior to setting up the H.E.R.O. Innovators Fund, KB was the Chief Investment Officer & CEO of a Singapore Registered Fund Management Company (RFMC) where he is responsible for listed Asian equity investments. KB had taught accounting at the Singapore Management University (SMU) as a faculty member and also pioneered the 15-week course on Accounting Fraud in Asia as an official module at SMU. KB remains grateful and honored to be invited by Singapore’s financial regulator Monetary Authority of Singapore (MAS) to present to their top management team about implementing a world’s first fact-based forward-looking fraud detection framework to bring about benefits for the capital markets in Singapore and for the public and investment community. KB also served the community in sharing his insights in writing articles about value investing and corporate governance in the media that include Business Times, Straits Times, Jakarta Post, Manual of Ideas, Investopedia, TedXWallStreet. He had also presented in top investment, banking and finance conferences in America, Italy, Sydney, Cape Town, HK, China. He has trained CEOs, entrepreneurs, CFOs, management executives in business strategy & business model innovation in Singapore, HK and China.

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

%d bloggers like this: